Roboz et al. reported the results relative to 34 newly diagnosed older adult AML patients from a phase I study enrolling patients with IDH1-mutant hematologic malignancies at advanced stage (Table 3). This evidence concerns the gene IDH1 and acute myeloid leukemia.